The shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) has been pegged with a rating of Buy by Maxim Group in its latest research note that was published on November 29th, 2018. The research company has also assigned a $3 price target. Maxim Group wasn’t the only research firm that published a report of Agile Therapeutics, Inc., with other equities research analysts also giving their opinion on the stock. William Blair advised investors in its research note published on December 26th, 2017, to Mkt Perform the AGRX stock. The stock had earned Neutral rating from Janney when it published its report on December 26th, 2017. The stock was given Buy rating by H.C. Wainwright in its report released on October 2nd, 2017, the day when the price target on the stock was placed at $10. RBC Capital Mkts was of a view that AGRX is Outperform in its latest report on September 14th, 2017 while giving it a price target of $10. H.C. Wainwright thinks that AGRX is worth Buy rating. This was contained in the firm’s report on July 19th, 2017 in which the stock’s price target was also moved to $10.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 2 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $3.00. The price of the stock the last time has raised by 291.86% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 61.57.

The shares of the company added by 1.71% during the trading session on Monday, reaching a low of $0.9 while ending the day at $0.91. During the trading session, a total of 2.99 million shares were traded which represents a -894925.58% decline from the average session volume which is 334.29K shares. AGRX had ended its last session trading at 0.89. Agile Therapeutics, Inc. currently has a market cap of $31.12M, with a beta of 0.34. Agile Therapeutics, Inc. debt-to-equity ratio currently stands at 0.25, while its quick ratio hovers at 2.10. AGRX 52-week low price stands at $0.23 while its 52-week high price is $3.92.

The company in its last quarterly report recorded -$0.11 earnings per share which is above the -$0.15 predicted by most analysts. In the second quarter last year, the firm recorded -$0.16 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -45.45%. Agile Therapeutics, Inc. has the potential to record -0.65 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on January 23rd, 2019 where it informed investors and clients that Capital One Financial Corporation (NYSE:COF) is now rated as Buy. Their price target on the stock stands at $106. William Blair also rated COF as Downgrade on December 26th, 2017, with its price target of $82 suggesting that COF could surge by 22.85% from its current share price. Even though the stock has been trading at $77.83/share, analysts expect it to surge higher by 0.27% to reach $101.16/share. It started the day trading at $78.4 and traded between $77.75 and $78.04 throughout the trading session.

A look at its technical shows that COF’s 50-day SMA is 80.23 while its 200-day SMA stands at 90.78. The stock has a high of $101.67 for the year while the low is $69.90. The company’s P/E ratio currently sits at 6.60, while the P/B ratio is 0.74. The company’s average trading volume currently stands at 3.01M shares, which means that the short-interest ratio is just 1.69 days. Over the past seven days, the company moved, with its shift of -4.12%. Looking further, the stock has dropped -13.81% over the past 90 days while it lost -20.06% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Dodge Cox sold more COF shares, decreasing its portfolio by -11.90% during the last quarter. This move now sees Dodge Cox selling -5,152,261 shares in the last quarter, thus it now holds 38,134,401 shares of COF, with a total valuation of $2,882,579,372. The Vanguard Group Inc meanwhile bought more COF shares in the recently filed quarter, changing its stake to $2,554,750,833 worth of shares. Capital Research Management Co followed the path by decreasing its COF portfolio by -13.94% in the quarter. This means that Capital Research Management Co sold -5,388,597 shares in the last quarter and now controls 33,279,548 shares of the COF stock, with the valuation hitting $2,515,601,033.

Similarly, BlackRock Fund Advisors decreased its Capital One Financial Corporation shares by -1.16% during the recently filed quarter. After selling -232,845 shares in the last quarter, the firm now controls 19,881,987 shares of Capital One Financial Corporation which are valued at $1,502,879,397. In the same vein, Fidelity Management Research Co decreased its Capital One Financial Corporation shares by during the most recent reported quarter. The firm sold -771,795 shares during the quarter which decreased its stakes to 16,675,056 shares and is now valued at $1,260,467,483. Following these latest developments, around 0.60% of Capital One Financial Corporation stocks are owned by institutional investors and hedge funds.